A. Dienst

发表

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

U. Germing, J. Neukirchen, R. Haas, 2011, Clinical Epigenetics.

Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins.

J. Fries, J. Nör, C. Gottstein, 2005, Journal of the National Cancer Institute.

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

I. Bruns, G. Kobbe, R. Fenk, 2009, Leukemia research.

Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis

K. Köhrer, I. Bruns, Ron-Patrick Cadeddu, 2016, International journal of cancer.

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

H. Goldschmidt, G. Kobbe, R. Fenk, 2020, Clinical Cancer Research.

Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid

U. Germing, R. Haas, O. Ottmann, 2008 .

Soluble Tissue Factor Induces Coagulation on Tumor Endothelial Cells In Vivo if Coadministered With Low-Dose Lipopolysaccharides

Andreas Engert, J. Fries, A. Engert, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

N. Kröger, T. Luft, U. Germing, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies

U. Germing, G. Kobbe, R. Fenk, 2019, Annals of Hematology.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

N. Kröger, Ron-Patrick Cadeddu, U. Germing, 2013, Leukemia.

Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.

D. Wieczorek, U. Germing, G. Kobbe, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sorafenib and azacitidine as salvage therapy for relapse of FLT3‐ITD mutated AML after allo‐SCT

U. Germing, G. Kobbe, R. Haas, 2017, European journal of haematology.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

W. Klapper, A. Ganser, C. Franzius, 2019, Annals of Hematology.

Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM).

H. Goldschmidt, N. Kröger, G. Kobbe, 2018 .

Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience

G. Kobbe, J. Neukirchen, R. Fenk, 2016 .

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

I. Bruns, G. Kobbe, R. Fenk, 2007 .